Centenial Surgical Suture Ltd vs Global Longlife Hospital And Research Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Centenial Surgical Suture Ltd is ₹ 78.31 as of 22 Jun 15:31 . The P/E Ratio of Centenial Surgical Suture Ltd changed from 24.1 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Global Longlife Hospital and Research Ltd changed from 25.7 on March 2023 to 0 on March 2026 . This represents a CAGR of -100.00% over 4 years The Market Cap of Centenial Surgical Suture Ltd changed from ₹ 15.6 crore on March 2021 to ₹ 27.83 crore on March 2026 . This represents a CAGR of 10.13% over 6 yearsThe Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 47.02 crore on March 2023 to ₹ 14.34 crore on March 2026 . This represents a CAGR of -25.69% over 4 years The revenue of Centenial Surgical Suture Ltd for the Jun '26 is ₹ 15.35 crore as compare to the Mar '26 revenue of ₹ 12.65 crore. This represent the growth of 21.34% The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Centenial Surgical Suture Ltd for the Jun '26 is ₹ 2.19 crore as compare to the Mar '26 ebitda of ₹ 1 crore. This represent the growth of 119% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Centenial Surgical Suture Ltd changed from ₹ 0.3 crore to ₹ 0.74 crore over 9 quarters. This represents a CAGR of 49.37% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The Dividend Payout of Centenial Surgical Suture Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Centenial Surgical Suture Ltd

Incorporated in 1995, Centenial Surgical Suture Limited is engaged in the manufacture and sale of surgical sutures in India.
The company offers absorbable sutures that include natural and synthetic sutures and non absorbable sutures comprising needles for cardiovascular surgery, monofilament polyamide atraumatic needle suture combinations, monofilament stainless steel, and temporary pacemaker electrodes.
It also provides female urinary incontinency sets, titanium haemostatic clips for cardiovascular surgery, non absorbable. Company leverages the expertise and application knowledge of the global suture requirements for cardiovascular sutures in particular, to bring advanced atraumatic needle product development to the Indian Surgeons.
Continuous innovation in the areas of design, research and development of atraumatic needle, simulation and validation, testing and services, are the key value creation driver for the Company.

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution that offer to every human being, high quality healthcare at affordable prices in Ahmedabad. Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

FAQs for the comparison of Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd

Which company has a larger market capitalization, Centenial Surgical Suture Ltd or Global Longlife Hospital and Research Ltd?

Market cap of Centenial Surgical Suture Ltd is 25 Cr while Market cap of Global Longlife Hospital and Research Ltd is 13 Cr

What are the key factors driving the stock performance of Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd?

The stock performance of Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd?

As of October 31, 2026, the Centenial Surgical Suture Ltd stock price is INR ₹71.25. On the other hand, Global Longlife Hospital and Research Ltd stock price is INR ₹12.82.

How do dividend payouts of Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd compare?

To compare the dividend payouts of Centenial Surgical Suture Ltd and Global Longlife Hospital and Research Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.